Evoglip- M

Composition: Sitagliptin 50 mg + Metformin 500 mg

Evoglip M5 is a combination anti-diabetic tablet containing Sitagliptin 50 mg and Metformin 500 mg. This dual therapy provides comprehensive sugar control: Metformin reduces liver glucose output and improves insulin sensitivity, while Sitagliptin enhances incretin activity for better post-meal insulin response. Evoglip M500 is commonly prescribed for patients whose blood sugar is not controlled with Metformin alone.

Uses:

• Type 2 Diabetes control
• Significant HbA1c reduction
• Better post-meal sugar control
• Helps in insulin regulation

Side Effects:

• Nausea, diarrhea, stomach upset (Metformin-related)
• Headache
• Respiratory infections
• Rare: lactic acidosis or pancreatitis

Other Details:

• Best taken with meals to avoid gastric issues
• Not recommended in severe kidney disease
• Supports weight maintenance